Background
Congenital chloride diarrhea (CLD; OMIM #214700) is a rare diasease with an autosomal recessive inheritance (Norio et al., 1971) . It is characterized by chronic secretory diarrhea containing an excess of chloride. Due to the intrauterine onset of diarrhea, CLD pregnancies are complicated by polyhydramnios and infant meconium is lacking (Holmberg, 1986) .
Children with CLD are often premature and soon after birth, profuse diarrhea leads to dehydration, hypochloremic and hypokalemic metabolic alkalosis, and failure to thrive. CLD diagnosis is based on the clinical picture and measurement of high fecal chloride (>90 mmol/L) after correction of the fluid and salt depletion. While untreated disease is mostly lethal during the first weeks or months of life, oral salt substitution with NaCl and KCl allows normal growth and development, and favorable outcome (Holmberg, 1986; Hihnala et al., 2006a; Wedenoja et al., 2010) . Untreated or poorly treated disease is associated with impaired renal function and nephrocalcinosis, and even with end-stage renal disease (Wedenoja et al., 2008b) . Associated morbidity involves intestinal inflammation, hyperuricemia, inguinal hernias, spermatoceles, and male subfertility (Hihnala et al., 2006a; Hoglund et al., 2006) .
After the first CLD descriptions in two Americans partly of Italian descent, more than 250
cases have been reported worldwide with around one-fifth of the patients originating from
Finland (Darrow, 1945; Gamble et al., 1945; Hoglund et al., 1998) . For the rarity of CLD, most of its clinical and genetic studies have been performed in the genetically homogeneous series of Finland, where the incidence is in the range of 1 in 30,000 to 40,000 live births. Hoglund et al., 1998) . Single cases with CLD appear worldwide, both in developing and more affluent countries, making diagnostics challenging. If a suspicion of CLD arises, especially in low-incidence countries, mutation analysis may be required to establish the diagnosis (Hoglund et al., 1996; Makela et al., 2002) .
CLD is caused by mutations in the solute carrier family 26 member 3 (SLC26A3) gene (OMIM #126650) (Kere et al., 1993; Hoglund et al., 1996) . Initially, SLC26A3 was cloned with the name down-regulated in adenoma (DRA) as a potential tumor suppressor gene based on its abundant expression in the colon but its absence from colonic adenomas and adenocarcinomas (Schweinfest et al., 1993; Taguchi et al., 1994) . The genomic sequence of SLC26A3 spans around 37.8 kb on the minus strand of chromosome 7q31.1 (www.ncbi.nlm.nih.gov: NG_008046.1). The full-length cDNA, around 3.2 kb on Northern blot (Schweinfest et al., 1993) (www.ncbi.nlm.nih.gov: NM_000111.2) , has an open reading frame of 2,295 bp, the 5´untranslated region (UTR) of 211 bp, and the 3´ UTR of 388 bp. The promoter region fragment flanking the area between -398 and -102 bp is responsible for the basal level of SLC26A3 transcription, and the region between -398 and -688 bp is necessary for high-level transcriptional activation induced by sodium butyrate (Alrefai et al., 2007) .
Total of 21 exons, of which 20 are coding, range from 55 to 234 bp in size. The translation start codon ATG (Met 1) in exon 2 is followed by the termination codon TAA in exon 21 (Haila et al., 1998) .
SLC26A3 encodes for an 85-kDa transmembrane glycoprotein with 764 amino acids forming the predicted 12 to 14 hydrophobic membrane-spanning domains in addition to the cytoplasmic N-and C-terminal domains (Byeon et al., 1996; Bairoch et al., 2005) . The SLC26A3 protein is an apical exchanger which transports Cl -across the apical cell membrane in exchange of HCO 3 - (Hoglund et al., 1996; Moseley et al., 1999) and in conjunction with other epithelial ion transporters (Melvin et al., 1999; Ko et al., 2002; Lamprecht and (Aravind and Koonin, 2000; Ko et al., 2002) .
Four C-terminal amino acids of SLC26A3, glutamic acid-threonine-lysine-phenylalanine (ETKF), form PDZ [postsynaptic density protein (PSD95), the Drosophila homologue Disclarge, and the tight junction protein ZO-1] interaction motif which interacts with several PDZ adapter proteins and couples the activity of SLC26A3 and Na + /H + exchanger 3 (NHE3) (Melvin et al., 1999; Lamprecht and Seidler, 2006) . Loss of the SLC26A3-mediated Cl -/HCO 3 -exchange activity in the ileum and colon, with secondary disruption of the Na + /H + transport, results in intestinal loss of both NaCl and fluid, and to the profuse diarrhea of CLD (Moseley et al., 1999; Melvin et al., 1999; Holmberg, 1978) .
In both humans and rodents, expression of SLC26A3 mRNA and protein emerges in the absorptive surface epithelium of the small intestine, especially in the ileum but also in the duodenum, and in the surface epithelium of the colon. In the intestinal crypts, the signal is lacking (Hoglund et al., 1996; Jacob et al., 2002) . In the human male reproductive tract, SLC26A3 expression appears in the testis, efferent ducts of the testis and proximal epididymis, and in the epithelium of the seminal vesicle (Hihnala et al., 2006b) . Moreover, SLC26A3 is expressed in the epithelium of the human sweat gland (Haila et al., 2000) . In cell cultures, expression of SLC26A3 appears in epithelial cells derived from the pancreatic duct (Greeley et al., 2001 ) and trachea (Wheat et al., 2000) . In intestinal adenomas and adenocarcinomas, expression of SLC26A3 is significantly down-regulated or even undetectable (Schweinfest et al., 1993; Antalis et al., 1998) . In addition to colon cancer, reduced SLC26A3 expression may play a role in the pathogenesis of ulcerative colitis (Yang et al., 1998; Asano et al., 2009) , and reduction of SLC26A3 promoter activity by the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   6 inflammatory mediator interferon-gamma (IFN-γ ) may contribute to the pathogenesis of intestinal inflammation (Alrefai et al., 2007) .
SLC26A3 belongs to he human solute carrier family 26 (SLC26) with 11 structurally homologous anion exchangers (Mount and Romero, 2004) . Three of these anion exchangers are associated with rare autosomal recessive diseases: SLC26A3 with CLD (OMIM #214700), SLC26A4 with Pendred syndrome (OMIM #274600) (Everett et al., 1997) , and SLC26A2 (alias DTDST) with a continuum of skeletal dysplasia phenotypes including diastrophic dysplasia (OMIM #222600), achondrogenesis type IB (OMIM #600972), atelosteogenesis type II (OMIM #256050), and multiple epiphyseal dysplasia (OMIM #226900) (Hastbacka et al., 1994; Superti-Furga et al., 1996; Hastbacka et al., 1996; SupertiFurga et al., 1999) .
Variants of the SLC26A3 gene
After finding that SLC26A3 causes CLD (Hoglund et al., 1996) , altogether 30 different mutations and 4 polymorphisms have been reported by the Finnish researchers (Makela et al., 2002) , and 4 mutations by others (Heinz-Erian et al., 2008; Choi et al., 2009) . When the 21 novel mutations of this paper are added to the spectrum of SLC26A3 mutations, these novel changes represent 38% of the total 55 mutations ( Table 1 ).
The reported SLC26A3 mutations have been identified by automated sequencing after PCR amplification of genomic DNA with intronic primers to cover all the exons and the complete coding sequence (Haila et al., 1998; Heinz-Erian et al., 2008) , except for the recent paper with 3 novel mutations identified by whole-exome sequencing (Choi et al., 2009) . The mutation nomenclature is partly different from the previous mutation update (Makela et al., 2002) and based on the current recommendations of the Human Genome Variation Society 
Mutation types
Majority of the SLC26A3 mutations are single-nucleotide substitutions (n=30; 55%). Of these, 13 are transversions with a substitution of a purine for a pyrimidine or vice versa, and 17 are transitions changing a purine to another purine or a pyrimidine to another pyrimidine.
This excess of transitional over transversional substitutions, resulting from the relatively high rate of mutation of methylated cytosines to thymine, is consistent with the findings throughout the genome (Arnheim and Calabrese, 2009 Additional mutations are minor deletions (n=15; 27%) and insertions (n=3; 5%) or their combinations (n=3; 5%). Only three major deletions (n=3; 5%) and one major insertion (n=1; 2%) have been found in association with CLD. All major deletions result in loss of one or several exons and, most likely, absence of the SLC26A3 protein. The largest deletion found in association with CLD is the 8.6 kb deletion reported in this study. This mutation was found in a Swedish patient with Lebanese origin. As for other mutations, direct sequencing was used in mutation analysis. After the failed PCR amplification of exon 1, we selected several SNPs (single nucleotide polymorpshims) in the promoter and intron 1 and identified the borders of the deletion by finding the closest markers to exon 1 present in the patient DNA.
Deleted: . Thereafter, we designed primers around the approximate deletion, spanning from 4.3 kb upstream and 4.2 kb downstream from the exon 1, and PCR amplified and sequenced the exact nucleotides around the breakpoint of the deletion. Similarly, we proved the carriership of this deletion in the parents who were first cousins. As this large deletion removes not only the non-coding exon 1 but also the promoter region essential for the basal level of SLC26A3 transcription (Alrefai et al., 2007) , it is the only mutation that, most likely, disrupts transcription of the gene. The clinical phenotype of this patient is, however, similar to that observed in other patients with different mutations for CLD.
When larger deletions and insertions or their combinations are excluded, all minor deletions and insertions except for 3 introduce a frame-shift with a change of some amino acids, and finally, stop codon terminating the protein synthesis. Those 3 CLD-associated mutations with in-frame deletion/insertion are the Finnish founder mutation c.951_953del (p.V318del) in exon 8, the Polish founder mutation c.2024_2026dup (p.I675dup) in exon 18, and c.1579_1581del (p.Y527del) in exon 14 found in one Polish patient (Table 1) .
Intragenic mutations
Among the all mutations, 82 % (n=45) are located in exons, 13 % (n=7) in or next to intronic splice sites, and 5% (n=3) involve deletion of both exonic and intronic sequences. Although the mutations are scattered across the whole gene, their distribution is uneven ( Figure 1A ). (Table 1 ). In the case of transitions, such as p.G120S, the likely mechanism for mutations is methylation of cytosine-guanine (CpG) dinucleotides while microdeletions and insertions scattered between the exons 12 and 15 may be associated with short nucleotide repeats (Makela et al., 2002; Arnheim and Calabrese, 2009 
Founder Mutations
In Finland, genetic studies of CLD have revealed the single ancestral founder mutation c.951_953del (p.V318del) in a homozygous form in all but one patient. Similarly, the founder mutation c.559G>T (p.G187X) accounts for >90% of CLD-causing mutations in Arab Countries, whereas the Polish major mutation c.2024_2026dup (p.I675dup) is involved in almost 50% of the CLD-associated chromosomes (Hoglund et al., 1998) . Outside these founder populations, mutation analysis is very likely to show rare, and often previously unreported, SLC26A3 mutations responsible for CLD (Table 1) . 
De Novo Mutations
So far, we have been able to verify the carriership of heterozygous SLC26A3 mutations in all the parental DNA samples studied for the mutation(s) found in their child with CLD.
Although de novo mutations remain nondetermined so far, the vast spectrum of SLC26A3 mutations suggests that novel mutations in this gene may be more common than expected based on the CLD incidence (Hoglund et al., 1998) .
Polymorphisms
All the SNPs reported in the coding region of SLC26A3 are presented in Table 1 . Of these 17
SNPs, 4 has been identified in association with genetic studies of CLD (Makela et al., 2002) and 16 exist in the dbSNP public database among the total of 311 SLC26A3 SNPs (Sherry et al., 2001) . Only 5 of the coding-area SNPs are silent, while the other SNPs alter the amino acid sequence (Table 1) . Functional data confirming the neutral role of an sequence altering variant exist only for the missense change c.921T>G (p.C307W) (Hoglund et al., 1996; Moseley et al., 1999) .
Biological Relevance

Animal Model of CLD
The SLC26A3 protein is the colon's most essential apical anion transporter. Evidence for this is not only the life-threatening diarrheal phenotype of CLD but also existence of SLC26A3-deficient mice with a diarrheal phenotype closely similar to that of CLD. SLC26A3-deficient mice exhibit, however, unique features uncharacteristic of human CLD. These include significant growth retardation, occasionally development of prolapsed rectums, and an aberrant growth pattern of the colonic mucosa with an expanded proliferative zone of colonic crypts and hyperplasia of the surface epithelium (Schweinfest et al., 2006) .
Protein structure
Although the exact structure of the SLC26A3 protein remains undetermined, the UniProt prediction suggests the presence of 12 to 14 transmembranic protein domains (Bairoch et al., 2005) . Using the prediction of 12 domains and those 45 mutations (82% of total 55 mutations) associated with the coding sequence only, 2 mutations are located in the cytoplasmic N terminal domain, 28 between the first and last transmembranic domain, and 15
in the cytoplasmic C terminus ( Figure 1B ).
STAS domain, the amino acids 525 to 720 (Aravind and Koonin, 2000; Bairoch et al., 2005) , involves 10 different mutations representing 18% of all mutations. The regulatory action through the R domain of CFTR and STAS domain of SLC26A3 seems to be essential for epithelial HCO 3 -secretion in the tissues where both these transporters are expressed, meaning at least the small intestine (Jacob et al., 2002; Greger, 2000; Rossmann et al., 2005) , pancreatic duct (Greeley et al., 2001; Ko et al., 2004) , and tracheal epithelium (Wheat et al., 2000) . As this essential physical association between CFTR and SLC26A3 requires intact R and STAS domains, and at least one CLD-causing mutation on the STAS domain of SLC26A3 prevent the activation of CFTR as well, CFTR may also play a role in the pathogenesis of CLD (Ko et al., 2004) .
None of the SLC26A3 mutations is located in the PDZ motif, comprising the four C-terminal amino acids. This motif enables the binding with PDZ adapter proteins and couples the action of SLC26A3 with other transporters such as NHE3 to promote electroneutral NaCl absorption (Melvin et al., 1999; Lamprecht and Seidler, 2006 (Melvin et al., 1999; Schweinfest et al., 2006) .
Functional Studies on SLC26A3 mutations
Functional data on mutant forms of SLC26A3 are limited. Regarding the Finnish founder mutation c.951_953del (p.V318del), the anion exchange activity is lacking despite the normal levels of SLC26A3 mRNA and protein in the CLD colon (Hoglund et al., 1996; Moseley et al., 1999; ). An associated feature of this mutation is a substitution of tryptophan for cysteine ten codons upstream c.921T>G (p.C307W), the frequency of which alone is around 14% in the healthy Finnish population. This variant is compatible with normal anion exchange activity, neutral in conjunction with the mutation c.951_953del (p.V318del), and is therefore considered a meaningless SLC26A3 polymorphism (Hoglund et al., 1996; Moseley et al., 1999 
Clinical and Diagnostic Relevance
Differential Diagnosis
The simple measurement of fecal Cl -is still sufficient to confirm the diagnosis in most of the cases. Differential diagnosis of CLD includes other inherited diarrheas such as congenital sodium diarrhea (Holmberg and Perheentupa, 1985; Booth et al., 1985) , glucose-galactose malabsorption (Martin et al., 1996) , congenital sucrase-isomaltase deficiency (Ouwendijk et al., 1996) , lysinuric protein intolerance, acrodermatitis enteropathica, and microvillus inclusion disease (Field, 2003) . In these diseases and in other secretory diarrheas, alkaline stool pH and metabolic acidosis exclude the possibility of CLD, the hallmarks of which are acidic stools and metabolic alkalosis (Holmberg, 1986; Field, 2003) . Importantly, CLD may be confused with other salt-wasting diseases, such as Bartter syndrome (Choi et al., 2009 ).
Genotype-Phenotype Correlation
Despite the various types of mutations and their wide distribution in different regions of the SLC26A3 gene, evidence of genotype-phenotype differences in CLD is nonexistent (Makela et al., 2002) . Even the identical genetic background of CLD may, however, result in variable clinical course if the diagnosis is delayed or salt substitution insufficient, resulting in severe dehydration, and thereby, reduction in the amount of diarrhea (Holmberg et al., 1977; Hoglund et al., 2001 ). In addition, the patients with even the same genotype may show different responses to diarrhea-modulating agents such as butyrate, shown to reduce the amount of diarrhea in an Italian patient but not in the Finnish series of CLD (Canani et al., 2004; Wedenoja et al., 2008a) . Whether different mutations modulate disease characteristics such as male subfertility, described only in the highly homogenous series of Finland so far (Hoglund et al., 2006) , remains to be determined. (p.V318del). After finding the gene for CLD (Hoglund et al., 1996) , more than 160 patients with a clinical suspicion have been tested for SLC26A3 mutations in our laboratory at research basis. Because CLD is rare and the outcome of treated disease is favorable, prenatal diagnostics or carrier testing are rarely requested or performed. In addition to our laboratory, some other research laboratories have recently reported CLD-associated SLC26A3 mutations (Heinz-Erian et al., 2008; Choi et al., 2009 ).
In patients originating from founder populations, a feasible strategy for mutation analysis is to search for the known founder mutations present in 99% of the Finnish, >90% of the Arabic, and around 50% of the Polish CLD-associated chromosomes (Hoglund et al., 1998 ).
In contrast, most patients outside these geographical regions are likely to have rare, and often previously unreported, homozygous or compound heterozygous mutations identified only through sequencing of the whole coding region of SLC26A3 (Table 1 ; Figure 1 ). At least rare homozygous mutations for CLD, such as the large homozygous deletion of 8.6 kb reported here, are likely to arise from areas where consanguineous marriages are relatively common, for instance from the countries around the Persian Gulf (Hoglund et al., 1998) . On the other hand, those rare mutations found in single patients from different countries may actually arise from the same population, and therefore, the country of residence may not reveal the roots of the families (Table 1) . Because single cases with CLD arise worldwide and the spectrum of mutations is wide, such CLD infrequency makes misdiagnoses highly probable. Especially in low-incidence countries, negative family history in association with difficulties in refining the early clinical diagnosis are likely to delay the diagnosis and result in lethal complications in early childhood, or in those with the delayed diagnosis, induce retarded growth, and later, development of chronic kidney disease (Wedenoja et al., 2008b) .
Our mutation analysis has failed to find CLD-causing mutations in 6 patients so far (Makela et al., 2002) . Certainly, any difficulties in assessing phenotypic characteristics may make genetic diagnostics unreliable, or alternatively, mutations may be localized in the areas uncovered by sequencing, such as promoter and non-coding regions outside the exon-intron boundaries. In addition, any major deletions or insertions may be simply missed through direct sequencing. Most probably, these events are relatively rare in association with CLD, supported by the high success rate of our mutation analysis and by the fact that larger deletions or insertions have been found in only 4 of these 165 patients studied so far (Table   1 ).
When many of the SLC26A3 mutations found are novel, prediction of their pathogenicity may remain uncertain without functional testing. SLC26A3 is, however, likely to be sensitive for any coding region mutations because (i) polymorphisms in the coding region are relatively rare (Table 1) , (ii) all the studied mutants result in loss of the Cl -/HCO 3 -activity (Moseley et al., 1999; Ko et al., 2002; Chernova et al., 2003; Dorwart et al., 2008) , and (iii) the clinical picture of CLD is invariable independently of genotype. Even up to the 8.6 kb deletion, reported in this study, results in the typical clinical course of CLD despite the fact that it eliminates the promoter region responsible for the basal level SLC26A3 transcription (Alrefai et al., 2007) . These data make assessment of mutations with unknown functional significance relatively conclusive if only the clinical picture is typical for CLD, a highly conserved amino acid is involved, mutations are confirmed on a second PCR product, and parental DNA samples prove the localization of compound heterozygous mutations on separate alleles. Although evidence of de novo mutations remain non-existent and we have found heterozygous changes in all parental samples studied, the spectrum of mutations suggests that novel SLC26A3 mutations are relatively common.
Future Prospects
Despite the advantages of genetic testing, large-scale mutation analysis is performed only as a part of research programs so far. Measuring high fecal chloride (>90 mmol/L) in a patient with a typical clinical picture and corrected electrolyte and acid-base balance is a reliable sign of CLD, independently of mutation analysis. As measurement of fecal chloride is fast and unexpensive, it remains to be the first line test to confirm/exclude the diagnosis of CLD.
It is worth remembering, however, that excessive volume and salt depletion reduces the amount of diarrhea and may result in a low fecal Cl -of even 40 mmol/L (Holmberg, 1978) .
Therefore, many patients are likely to die before the diagnosis and treatment, and in those suspected cases of CLD, mutation data may be essential to confirm the unsure diagnosis.
Establishment of local sequencing possibilities for the countries with a higher-than-average incidence of CLD and with known founder mutations would be easy and reliable in the first line diagnostics of CLD. In the future, genetic testing will most probably become easier and faster, allowing genetic diagnostics for CLD and other rare diseases locally. Outside the known founder populations for CLD, a future prospect is that the spectrum of found SLC26A3 mutations will expand, and hopefully, many of the patients with CLD will get their diagnosis based on both early clinical characterization and mutation analysis. Only better diagnostics could reveal the figures of incidence of CLD which, most probably, are notably higher than expected based on those around 250 cases reported so far. Finally, only the analysis of different genotypes in relation to phenotypes could provide data on genotypicphenotypic differences-if any-in CLD. which are shown with the dashed line (Aravind and Koonin, 2000; Bairoch et al., 2005) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Sherry et al., 2001 ). *U14569.1 indicates the GenBank accession of human Alu-Sb1 (Alu Y) subfamily consensus sequence (HSU14569). Mutation data are based on the RefSeq sequences NG_008046.1 (genomic) and NM_000111.2 (cDNA).
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Human Mutation
